FI3246070T3 - Uusia fxr:ää (nr1h4) sitovia ja aktiivisuutta muokkaavia atsoleja - Google Patents
Uusia fxr:ää (nr1h4) sitovia ja aktiivisuutta muokkaavia atsoleja Download PDFInfo
- Publication number
- FI3246070T3 FI3246070T3 FIEP17000383.4T FI17000383T FI3246070T3 FI 3246070 T3 FI3246070 T3 FI 3246070T3 FI 17000383 T FI17000383 T FI 17000383T FI 3246070 T3 FI3246070 T3 FI 3246070T3
- Authority
- FI
- Finland
- Prior art keywords
- lääkekoostumus
- mukaisesti
- käytettävä
- patenttivaatimuksen
- formuloitu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507153P | 2011-07-13 | 2011-07-13 | |
| EP11005722A EP2545964A1 (en) | 2011-07-13 | 2011-07-13 | Novel FXR (NR1H4) binding and activity modulating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3246070T3 true FI3246070T3 (fi) | 2024-04-18 |
Family
ID=44513243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17000383.4T FI3246070T3 (fi) | 2011-07-13 | 2012-07-12 | Uusia fxr:ää (nr1h4) sitovia ja aktiivisuutta muokkaavia atsoleja |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9139539B2 (https=) |
| EP (5) | EP2545964A1 (https=) |
| JP (2) | JP5986633B2 (https=) |
| KR (4) | KR101766323B1 (https=) |
| CN (2) | CN107252424B (https=) |
| AR (1) | AR087127A1 (https=) |
| AU (4) | AU2012283387C1 (https=) |
| BR (3) | BR112014000260B1 (https=) |
| CA (1) | CA2839357C (https=) |
| CY (1) | CY1117453T1 (https=) |
| DK (2) | DK3246070T3 (https=) |
| EA (1) | EA024843B1 (https=) |
| ES (3) | ES2632492T3 (https=) |
| FI (1) | FI3246070T3 (https=) |
| HR (2) | HRP20160442T1 (https=) |
| HU (2) | HUE066734T2 (https=) |
| IL (1) | IL229944A (https=) |
| LT (1) | LT3246070T (https=) |
| ME (1) | ME02434B (https=) |
| MX (2) | MX368371B (https=) |
| MY (1) | MY161158A (https=) |
| PH (1) | PH12014500124A1 (https=) |
| PL (3) | PL3246070T3 (https=) |
| PT (2) | PT2987532T (https=) |
| RS (1) | RS54786B1 (https=) |
| SI (3) | SI2731676T1 (https=) |
| SM (1) | SMT201600169B (https=) |
| TW (1) | TWI439455B (https=) |
| UY (1) | UY34196A (https=) |
| WO (1) | WO2013007387A1 (https=) |
| ZA (1) | ZA201309521B (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| IL253437A0 (en) * | 2011-07-13 | 2017-09-28 | Gilead Sciences Inc | New compounds modulate fxr (nr1h4) activity and bind |
| DK3043865T3 (da) | 2013-09-11 | 2021-02-01 | Univ Claude Bernard Lyon | Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion |
| EP3197448B1 (en) | 2014-09-24 | 2019-04-24 | Gilead Sciences, Inc. | Methods of treating liver disease |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| MX2017008057A (es) * | 2014-12-18 | 2017-09-28 | Novartis Ag | Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales. |
| TWI685491B (zh) | 2014-12-23 | 2020-02-21 | 美商基利科學股份有限公司 | 製備５-（４-環丙基-１ｈ-咪唑-１-基）-ｎ-（６-（４-異丙基-４ｈ-１,２,４-三唑-３-基）吡啶-２-基）-２-氟-４-甲基苯甲醯胺之方法 |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2016161003A1 (en) | 2015-03-31 | 2016-10-06 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| KR101974793B1 (ko) | 2015-07-06 | 2019-05-02 | 길리애드 사이언시즈, 인코포레이티드 | Cot 조정제 및 그의 사용 방법 |
| CN106995416A (zh) * | 2016-01-26 | 2017-08-01 | 上海翰森生物医药科技有限公司 | Fxr激动剂及其制备方法和应用 |
| WO2017128896A1 (zh) * | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
| TW201741307A (zh) * | 2016-02-22 | 2017-12-01 | 艾洛斯生物製藥公司 | Ｆｘｒ調節劑及其使用方法 |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| AU2017248354A1 (en) | 2016-04-08 | 2018-10-04 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| WO2017189651A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201150A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| MX385718B (es) | 2016-06-13 | 2025-03-18 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
| CA3252823A1 (en) * | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| AR108711A1 (es) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| CN106237332A (zh) * | 2016-08-11 | 2016-12-21 | 河南大学 | 核受体fxr在肝癌干细胞靶向治疗中的应用 |
| US10450306B2 (en) | 2016-10-04 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN107973790A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| WO2018081285A1 (en) * | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| CA3042398A1 (en) * | 2016-11-11 | 2018-05-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| CN106588804B (zh) * | 2016-12-09 | 2018-11-09 | 都创(上海)医药科技有限公司 | 一种作为类法尼醇x受体(fxr)的化合物的制备方法 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| WO2018133730A1 (zh) * | 2017-01-20 | 2018-07-26 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
| KR20190117632A (ko) | 2017-02-21 | 2019-10-16 | 장피트 | Ppar 효현제와 fxr 효현제의 병용 |
| WO2018169742A1 (en) | 2017-03-14 | 2018-09-20 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibtor |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| BR112019020780A2 (pt) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
| PL3612520T3 (pl) | 2017-04-12 | 2022-03-21 | Il Dong Pharmaceutical Co., Ltd. | Pochodne izoksazolu jako agoniści receptora jądrowego i ich zastosowania |
| AU2018250614A1 (en) * | 2017-04-12 | 2019-10-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| WO2018231851A1 (en) | 2017-06-13 | 2018-12-20 | Gilead Sciences, Inc. | Methods of treating liver fibrosis |
| KR102419458B1 (ko) | 2017-10-06 | 2022-07-12 | 길리애드 사이언시즈, 인코포레이티드 | Acc 억제제를 포함하는 조합 요법 |
| KR102731924B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| PE20201170A1 (es) | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x |
| CN111511731B (zh) | 2017-11-01 | 2023-05-23 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃化合物 |
| CN111278817B (zh) | 2017-11-01 | 2023-05-16 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的多环化合物 |
| AU2018360575A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| ES2986647T3 (es) | 2017-11-13 | 2024-11-12 | Gilead Sciences Inc | Método de estadificación de la fibrosis hepática en pacientes con EHNA |
| WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CN112638473B (zh) * | 2018-08-08 | 2022-06-07 | 因奥必治疗有限公司 | 用于调节类法尼醇x受体的化合物以及制备和使用所述化合物的方法 |
| WO2020029908A1 (zh) * | 2018-08-08 | 2020-02-13 | 广州市恒诺康医药科技有限公司 | 螺桥环化合物、其药物组合物及其用途 |
| AU2019344903B2 (en) | 2018-09-18 | 2025-02-27 | Eli Lilly And Company | Farnesoid X receptor agonists and uses thereof |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| EP3911647B1 (en) | 2019-01-15 | 2023-12-13 | Gilead Sciences, Inc. | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| JP7465883B2 (ja) | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CN113727973B (zh) | 2019-02-15 | 2025-08-29 | 百时美施贵宝公司 | 可用作类法尼醇x受体调节剂的取代酰胺化合物 |
| AU2020221371A1 (en) | 2019-02-15 | 2021-10-07 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| CA3233305A1 (en) * | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| AU2020234929B2 (en) * | 2019-03-11 | 2023-09-14 | Gilead Sciences, Inc. | Formulations of a compound and uses thereof |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| KR20220155356A (ko) | 2020-03-18 | 2022-11-22 | 메타크린, 인크. | 파르네소이드 x 수용체 효능제의 결정형 |
| WO2021188695A1 (en) | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formulations of a farnesoid x receptor agonist |
| CN120732855A (zh) * | 2020-03-18 | 2025-10-03 | 伊莱利利公司 | 用于治疗疾病的法尼醇x受体激动剂 |
| US20240043418A1 (en) | 2020-03-26 | 2024-02-08 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators |
| AU2021249010B2 (en) | 2020-03-30 | 2024-09-26 | Gilead Sciences, Inc. | Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| JP7446475B2 (ja) | 2020-04-02 | 2024-03-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｏｔ阻害剤化合物を調製するためのプロセス |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CN114656460B (zh) * | 2020-12-22 | 2025-01-10 | 江苏天士力帝益药业有限公司 | 一种新型吡嗪结构fxr激动剂、制备方法及应用 |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| CA3214961A1 (en) | 2021-03-29 | 2022-10-06 | Gilead Sciences, Inc. | Khk inhibitors |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療ｎａｓｈ之方法 |
| US11919879B2 (en) | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
| TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| WO2023125904A1 (zh) * | 2021-12-30 | 2023-07-06 | 苏州晶云药物科技股份有限公司 | 氮杂环丁基烟酸类化合物的晶型及其制备方法 |
| CA3268997A1 (en) | 2022-10-25 | 2024-05-02 | Assia Chemical Industries Ltd. | SOLID FORMS OF CILOFEXOR SALTS |
Family Cites Families (186)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193011A (en) | 1979-03-19 | 1983-03-15 | Ici Australia Ltd | Diarylamine derivatives intermediates herbicidal compositions |
| EP0287959B1 (de) | 1987-04-21 | 1993-04-28 | BASF Aktiengesellschaft | p-Phenoxy-phenoxymethyl-fünfring-heteroaromaten |
| JP3121061B2 (ja) | 1991-10-04 | 2000-12-25 | 塩野義製薬株式会社 | アルコキシイミノアセトアミド類製造用中間体の製造法およびそれに用いる中間体 |
| DE4137940A1 (de) | 1991-11-18 | 1993-05-19 | Basf Ag | 3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung |
| US5258551A (en) | 1991-12-18 | 1993-11-02 | Shionogi & Co., Ltd. | Process for producing α-ketoamide derivative |
| AU5891494A (en) | 1993-01-29 | 1994-08-15 | Nippon Soda Co., Ltd. | Heterocyclic derivative |
| WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
| IL112721A0 (en) | 1994-03-10 | 1995-05-26 | Zeneca Ltd | Azole derivatives |
| JPH10503768A (ja) | 1994-08-02 | 1998-04-07 | メルク シヤープ エンド ドーム リミテツド | アゼチジン、ピロリジンおよびピペリジン誘導体 |
| GB9501865D0 (en) | 1995-01-31 | 1995-03-22 | Merck Sharp & Dohme | Therapeutic agents |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| DE19536811A1 (de) | 1995-10-02 | 1997-04-03 | Basf Ag | Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel |
| AU1952597A (en) | 1996-02-13 | 1997-09-02 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
| DE69940958D1 (de) | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
| CN1368975A (zh) | 1999-06-11 | 2002-09-11 | 阿勒根销售公司 | 具有核激素受体调节活性的有机硅化合物 |
| CA2429426A1 (en) | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
| US20040105885A1 (en) | 2001-04-17 | 2004-06-03 | Ping Gao | Gelatin capsule exhibiting reduced cross-linking |
| US20040131670A1 (en) | 2001-04-17 | 2004-07-08 | Ping Gao | Pellicle-resistant gelatin capsule |
| US20040105883A1 (en) | 2001-04-17 | 2004-06-03 | Ping Gao | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| US20040105884A1 (en) | 2001-04-17 | 2004-06-03 | Ping Gao | Pharmaceutical dosage form comprising a sulfite compound |
| EP1405636A4 (en) | 2001-06-26 | 2009-04-15 | Takeda Pharmaceutical | FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| WO2003015777A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| US20070010562A1 (en) | 2001-08-13 | 2007-01-11 | Ulrike Bauer | Nr1h4 nuclear receptor binding compounds |
| US20050107475A1 (en) | 2002-03-21 | 2005-05-19 | Jones Stacey A. | Methods of using farnesoid x receptor (frx) agonists |
| US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| MXPA05001592A (es) | 2002-08-09 | 2005-05-05 | Astrazeneca Ab | Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico. |
| EP1407774A1 (en) | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
| WO2004046162A2 (en) | 2002-11-14 | 2004-06-03 | The Scripps Research Institute | Non-steroidal fxr agonists |
| US20050143449A1 (en) | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| WO2004048349A1 (en) | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| US20070166710A1 (en) | 2003-03-31 | 2007-07-19 | Markus Stoffel | Methods for inhibiting adipogenesis and for treating type 2 diabetes |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| BRPI0511099A (pt) | 2004-05-14 | 2007-12-26 | Irm Llc | compostos e composições como moduladores de ppar |
| MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| EP1799659A1 (en) | 2004-10-13 | 2007-06-27 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
| EP1894919B1 (en) | 2005-06-07 | 2012-03-28 | Shionogi & Co., Ltd. | Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity |
| JP5420908B2 (ja) | 2005-12-15 | 2014-02-19 | エグゼリクシス， インコーポレイテッド | 医薬的薬剤としてのアゼピノインドール誘導体 |
| WO2007076260A2 (en) | 2005-12-19 | 2007-07-05 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| CA2640476A1 (en) | 2006-02-03 | 2007-08-16 | Eli Lilly And Company | Compounds and methods for modulating fx-receptors |
| CN101395170A (zh) * | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| WO2007118323A1 (en) | 2006-04-17 | 2007-10-25 | Neuromed Pharmaceuticals Ltd. | Isoxazole derivatives as calcium channel blockers |
| TW200812982A (en) * | 2006-05-24 | 2008-03-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CN101448791B (zh) * | 2006-05-24 | 2011-11-16 | 伊莱利利公司 | Fxr激动剂 |
| CN101448798A (zh) * | 2006-05-24 | 2009-06-03 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
| EP2029600B1 (de) | 2006-05-24 | 2012-03-14 | Boehringer Ingelheim International GmbH | Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind |
| US7932244B2 (en) | 2006-06-27 | 2011-04-26 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| PE20080401A1 (es) | 2006-07-07 | 2008-06-23 | Boehringer Ingelheim Int | DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS |
| EP2041114B1 (en) | 2006-07-07 | 2016-03-02 | NephroGenex, Inc. | Inhibitors of advanced glycation end products |
| EP1894924A1 (en) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| US8501933B2 (en) | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| GB0625842D0 (en) | 2006-12-22 | 2007-02-07 | Argenta Discovery Ltd | Indolizine derivatives |
| US20090105251A1 (en) | 2007-01-25 | 2009-04-23 | Benjamin Jones | Renin inhibitors |
| BRPI0721218A2 (pt) | 2007-02-09 | 2013-01-01 | Dow Agrosciences Llc | processo para a oxidação de determinadas sulfiliminas substituìdas para sulfoximinas inseticidas |
| US7511149B2 (en) | 2007-02-09 | 2009-03-31 | Dow Agrosciences Llc | Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines |
| KR101437710B1 (ko) | 2007-02-26 | 2014-09-03 | 다우 아그로사이언시즈 엘엘씨 | 특정 치환된 술필이민의 제조 방법 |
| KR20100038102A (ko) | 2007-06-13 | 2010-04-12 | 글락소스미스클라인 엘엘씨 | 파네소이드 ｘ 수용체 작용제 |
| JP2008308448A (ja) | 2007-06-15 | 2008-12-25 | Sankyo Agro Kk | （３−硫黄原子置換フェニル）へテロアリール誘導体 |
| WO2008155054A1 (en) | 2007-06-20 | 2008-12-24 | F. Hoffmann-La Roche Ag | Farnesoid-x-receptor mutants, and crystallisation thereof |
| US20100240657A1 (en) | 2007-07-02 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| MX2009013946A (es) | 2007-07-02 | 2010-03-10 | Glaxosmithkline Llc | Agonistas del receptor de farnesoide x. |
| EA201000051A1 (ru) | 2007-07-13 | 2010-08-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Противовирусные соединения, композиции и способы использования |
| US20090197880A1 (en) | 2007-07-13 | 2009-08-06 | Genelabs Technologies, Inc. | Anti-viral compounds, compositions, and methods of use |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CN101790374A (zh) | 2007-08-01 | 2010-07-28 | H.隆德贝克有限公司 | Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途 |
| US8188080B2 (en) | 2007-10-17 | 2012-05-29 | Sanford-Burnham Medical Research Institute | VHR protein tyrosine phosphatase inhibitors, compositions and methods of use |
| US20090143451A1 (en) | 2007-11-14 | 2009-06-04 | Andrews William H | Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| EP2418207A1 (en) | 2008-05-13 | 2012-02-15 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the CB2 receptor |
| JP2011521916A (ja) | 2008-05-19 | 2011-07-28 | バーナム インスティテュート フォー メディカル リサーチ | 腸アルカリホスファターゼモジュレーターおよびそれの使用 |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| US8119637B2 (en) | 2008-06-10 | 2012-02-21 | Plexxikon Inc. | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| CN102105447B (zh) | 2008-06-23 | 2014-06-04 | 巴斯夫欧洲公司 | 防治动物害虫的磺酰亚胺酰胺化合物 |
| US20100029655A1 (en) | 2008-07-11 | 2010-02-04 | Martin Robert Leivers | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them |
| JP2012500848A (ja) | 2008-08-25 | 2012-01-12 | ダウ グローバル テクノロジーズ エルエルシー | イソオキサゾール化合物の製造方法 |
| WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| AU2009296048A1 (en) | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as FXR modulators against dyslipidemia and related diseases |
| WO2010034657A1 (en) | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives |
| WO2010036362A1 (en) | 2008-09-26 | 2010-04-01 | Wyeth | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| NZ592603A (en) | 2008-10-21 | 2013-02-22 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof |
| CA2744946A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| WO2010093191A2 (en) | 2009-02-13 | 2010-08-19 | Lg Life Sciences Ltd. | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
| FR2943059A1 (fr) | 2009-03-16 | 2010-09-17 | Sanofi Aventis | Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique |
| WO2011003793A1 (en) | 2009-07-06 | 2011-01-13 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| WO2011009804A2 (en) | 2009-07-24 | 2011-01-27 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011026241A1 (en) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Substituted heterocyclic derivatives for the treatment of pain and epilepsy |
| WO2011047129A1 (en) | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| MX2012010115A (es) | 2010-03-01 | 2013-02-26 | Gtx Inc | Compuestos para el tratamiento de cancer. |
| EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2012058531A2 (en) | 2010-10-29 | 2012-05-03 | North Carolina State University | Modulation of response regulators by imidazole derivatives |
| TWI408128B (zh) | 2010-12-03 | 2013-09-11 | Nat Univ Tsing Hua | 間-三聯苯衍生物及其在有機發光二極體之應用 |
| EP2655368A1 (en) | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| WO2012087521A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| SI3336097T1 (sl) | 2012-06-19 | 2021-07-30 | Intercept Pharmaceuticals, Inc. | Priprava nekristalinične oblike obetiholne kisline |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| TN2015000497A1 (en) | 2013-05-14 | 2017-04-06 | Intercept Pharmaceuticals Inc | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| BR112016002268B1 (pt) | 2013-08-01 | 2022-11-01 | The Penn State Research Foundation | Uso de inibidores do receptor x farnesoide |
| DK3043865T3 (da) | 2013-09-11 | 2021-02-01 | Univ Claude Bernard Lyon | Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion |
| US20150082981A1 (en) | 2013-09-20 | 2015-03-26 | E I Du Pont De Nemours And Company | Capture of trifluoromethane using ionic liquids |
| CN104513213A (zh) | 2013-09-28 | 2015-04-15 | 山东亨利医药科技有限责任公司 | Fxr激动剂 |
| US20150119345A1 (en) | 2013-10-29 | 2015-04-30 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of gastrointestinal infections |
| BR112016009630B1 (pt) | 2013-11-05 | 2021-02-09 | Novartis Ag | receptores de farnesoide x, seus usos, combinação e composição farmacêutica |
| WO2015116856A2 (en) | 2014-01-29 | 2015-08-06 | City Of Hope | Farnesoid x receptor antagonists |
| KR20160132111A (ko) | 2014-03-13 | 2016-11-16 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Fxr 작용제와 제조방법 및 용도 |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| EP3116851B1 (en) | 2014-03-13 | 2023-07-26 | Salk Institute for Biological Studies | Analogs of fexaramine and methods of making and using |
| AR100073A1 (es) | 2014-04-14 | 2016-09-07 | Gruenenthal Gmbh | Sulfonas heterocíclicas sustituidas con heteroarilos |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| WO2015162244A1 (en) | 2014-04-25 | 2015-10-29 | Basf Se | N-acylamidine compounds |
| WO2015165960A1 (en) | 2014-04-30 | 2015-11-05 | Basf Se | N-acylamidine compounds |
| SMT202000070T1 (it) | 2014-05-29 | 2020-03-13 | Bar Pharmaceuticals S R L | Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1 |
| CN104045635A (zh) | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| WO2016054560A1 (en) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| WO2016068585A1 (ko) | 2014-10-27 | 2016-05-06 | 주식회사 엘지화학 | 유기 전계 발광 소자 |
| SG11201703717SA (en) | 2014-11-06 | 2017-06-29 | Enanta Pharm Inc | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| CA2968434A1 (en) | 2014-11-21 | 2016-05-26 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| MX2017008057A (es) | 2014-12-18 | 2017-09-28 | Novartis Ag | Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales. |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| BR112017015273A2 (pt) | 2015-01-20 | 2018-01-09 | Merial Inc. | compostos e composições antihelmínticos e método de utilizações dos mesmos |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| CN106146483A (zh) | 2015-04-23 | 2016-11-23 | 上海迪诺医药科技有限公司 | 杂环类法尼酯衍生物x受体调节剂 |
| GB201507340D0 (en) | 2015-04-29 | 2015-06-10 | Univ St Andrews | Light emitting devices and compounds |
| ES2550374B1 (es) * | 2015-06-30 | 2016-09-08 | Universidad De La Rioja | Compuestos fotoprotectores análogos de MAA, procedimiento de síntesis y composición que comprende los mismos |
| US20180192651A1 (en) | 2015-07-13 | 2018-07-12 | Vanderbilt University | Thermal volatilization of orco agonists |
| EP3892718A1 (en) | 2015-09-11 | 2021-10-13 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| UY37005A (es) | 2015-12-04 | 2017-06-30 | Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware | Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos |
| WO2017097870A1 (de) | 2015-12-11 | 2017-06-15 | Bayer Cropscience Aktiengesellschaft | Substituierte malonsäureamide als insektizide |
| CN106946867B (zh) | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| WO2017117687A1 (en) | 2016-01-10 | 2017-07-13 | British Columbia Cancer Agency Branch | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| WO2017122209A2 (en) | 2016-01-12 | 2017-07-20 | Yeda Research And Development Co. Ltd. | NF-kappaB INHIBITORS |
| WO2017128896A1 (zh) | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
| CN107021957A (zh) | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| WO2017133521A1 (zh) | 2016-02-01 | 2017-08-10 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| CN107021958A (zh) | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| TW201741307A (zh) | 2016-02-22 | 2017-12-01 | 艾洛斯生物製藥公司 | Ｆｘｒ調節劑及其使用方法 |
| CN107224583A (zh) | 2016-03-24 | 2017-10-03 | 中美华世通生物医药科技（武汉）有限公司 | 药物组合物及其用途 |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| SG11201810602YA (en) | 2016-06-03 | 2018-12-28 | Chemocentryx Inc | Method of treating liver fibrosis |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| MX385718B (es) | 2016-06-13 | 2025-03-18 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| WO2018039384A1 (en) | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
| CN116854681A (zh) | 2016-08-23 | 2023-10-10 | 阿德利克斯股份有限公司 | 用于治疗代谢病状和病症的激素受体调节剂 |
| CN108430998B (zh) | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
| US20200045972A1 (en) | 2016-09-29 | 2020-02-13 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazolylmethyl derivatives |
| US10450306B2 (en) | 2016-10-04 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN107973790A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| IL311409A (en) | 2016-11-10 | 2024-05-01 | Galmed Res And Development Ltd | Use of Amcol for the treatment of fibrosis |
| CA3042398A1 (en) | 2016-11-11 | 2018-05-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| CN106588804B (zh) | 2016-12-09 | 2018-11-09 | 都创(上海)医药科技有限公司 | 一种作为类法尼醇x受体(fxr)的化合物的制备方法 |
| CN106632294A (zh) | 2016-12-15 | 2017-05-10 | 宁波百纳西药业有限公司 | 一种螺环化合物及其药物用途 |
| CN106748922B (zh) | 2017-01-12 | 2019-02-01 | 中国药科大学 | 一类新型砜酸衍生物、其制备方法及其作为药物的用途 |
-
2011
- 2011-07-13 EP EP11005722A patent/EP2545964A1/en not_active Withdrawn
-
2012
- 2012-07-02 TW TW101123785A patent/TWI439455B/zh active
- 2012-07-11 AR ARP120102511A patent/AR087127A1/es active IP Right Grant
- 2012-07-12 EP EP15002478.4A patent/EP2987532B1/en active Active
- 2012-07-12 MX MX2014000534A patent/MX368371B/es active IP Right Grant
- 2012-07-12 US US14/232,118 patent/US9139539B2/en active Active
- 2012-07-12 EP EP24164624.9A patent/EP4400503A3/en active Pending
- 2012-07-12 HR HRP20160442TT patent/HRP20160442T1/hr unknown
- 2012-07-12 BR BR112014000260-6A patent/BR112014000260B1/pt active IP Right Grant
- 2012-07-12 EA EA201391674A patent/EA024843B1/ru unknown
- 2012-07-12 MY MYPI2013004373A patent/MY161158A/en unknown
- 2012-07-12 DK DK17000383.4T patent/DK3246070T3/da active
- 2012-07-12 RS RS20160266A patent/RS54786B1/sr unknown
- 2012-07-12 HR HRP20240422TT patent/HRP20240422T1/hr unknown
- 2012-07-12 HU HUE17000383A patent/HUE066734T2/hu unknown
- 2012-07-12 BR BR122020008872-9A patent/BR122020008872B1/pt active IP Right Grant
- 2012-07-12 KR KR1020177000763A patent/KR101766323B1/ko active Active
- 2012-07-12 AU AU2012283387A patent/AU2012283387C1/en active Active
- 2012-07-12 SI SI201230535A patent/SI2731676T1/sl unknown
- 2012-07-12 CN CN201710308892.5A patent/CN107252424B/zh active Active
- 2012-07-12 WO PCT/EP2012/002941 patent/WO2013007387A1/en not_active Ceased
- 2012-07-12 DK DK12735100.5T patent/DK2731676T3/en active
- 2012-07-12 KR KR1020177021651A patent/KR101859533B1/ko active Active
- 2012-07-12 PT PT150024784T patent/PT2987532T/pt unknown
- 2012-07-12 SI SI201230969A patent/SI2987532T1/sl unknown
- 2012-07-12 PL PL17000383.4T patent/PL3246070T3/pl unknown
- 2012-07-12 LT LTEP17000383.4T patent/LT3246070T/lt unknown
- 2012-07-12 EP EP12735100.5A patent/EP2731676B1/en active Active
- 2012-07-12 ME MEP-2016-81A patent/ME02434B/me unknown
- 2012-07-12 FI FIEP17000383.4T patent/FI3246070T3/fi active
- 2012-07-12 CN CN201280033148.4A patent/CN103702719B/zh active Active
- 2012-07-12 PH PH1/2014/500124A patent/PH12014500124A1/en unknown
- 2012-07-12 PT PT170003834T patent/PT3246070T/pt unknown
- 2012-07-12 KR KR1020187013304A patent/KR101934335B1/ko active Active
- 2012-07-12 JP JP2014519453A patent/JP5986633B2/ja active Active
- 2012-07-12 KR KR1020147002937A patent/KR101722410B1/ko active Active
- 2012-07-12 EP EP17000383.4A patent/EP3246070B1/en active Active
- 2012-07-12 PL PL15002478T patent/PL2987532T3/pl unknown
- 2012-07-12 PL PL12735100T patent/PL2731676T3/pl unknown
- 2012-07-12 SI SI201232062T patent/SI3246070T1/sl unknown
- 2012-07-12 ES ES15002478.4T patent/ES2632492T3/es active Active
- 2012-07-12 ES ES12735100.5T patent/ES2569718T3/es active Active
- 2012-07-12 BR BR122019026062-1A patent/BR122019026062B1/pt active IP Right Grant
- 2012-07-12 CA CA2839357A patent/CA2839357C/en active Active
- 2012-07-12 UY UY0001034196A patent/UY34196A/es active IP Right Grant
- 2012-07-12 HU HUE12735100A patent/HUE027931T2/en unknown
- 2012-07-12 ES ES17000383T patent/ES2978166T3/es active Active
-
2013
- 2013-12-17 IL IL229944A patent/IL229944A/en active IP Right Grant
- 2013-12-17 ZA ZA2013/09521A patent/ZA201309521B/en unknown
-
2014
- 2014-01-13 MX MX2019011629A patent/MX2019011629A/es unknown
-
2015
- 2015-08-12 US US14/824,971 patent/US9539244B2/en active Active
-
2016
- 2016-04-28 CY CY20161100369T patent/CY1117453T1/el unknown
- 2016-06-10 SM SM201600169T patent/SMT201600169B/it unknown
- 2016-08-05 JP JP2016154511A patent/JP6321097B2/ja active Active
- 2016-11-29 AU AU2016265993A patent/AU2016265993B2/en active Active
- 2016-12-05 US US15/369,521 patent/US9820979B2/en active Active
-
2017
- 2017-10-13 US US15/783,530 patent/US10220027B2/en active Active
-
2018
- 2018-05-22 AU AU2018203613A patent/AU2018203613B2/en active Active
-
2019
- 2019-01-15 US US16/248,178 patent/US10485795B2/en active Active
- 2019-11-04 AU AU2019261667A patent/AU2019261667B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3246070T3 (fi) | Uusia fxr:ää (nr1h4) sitovia ja aktiivisuutta muokkaavia atsoleja | |
| MX374412B (es) | Una composición que comprende un inhibidor de pde3/pde4 o una sal de adición del mismo y un antagonista del receptor muscarínico. | |
| EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
| CR20140332A (es) | Inhibidores de bromodominios | |
| EP2548388A4 (en) | Methods, systems, and computer readable media for communicating policy information between a policy charging and rules function and a service node | |
| CL2019003647S1 (es) | Parte de interfaz de una batería. | |
| BRPI0924063A2 (pt) | Aglutinantes de látex, tintas e revestimentos aquosos tendo estabilidade de congelamento e descongelamento e métodos para usar mesmo | |
| BR112014010813A2 (pt) | n-(tetrazol-5-il)-aril-carboxamidas e n-(triazol-5-il)-aril-carboxamidas substituídas em 5-fenilo e sua utilização como herbicidas | |
| BRPI0906737A2 (pt) | Aglutinanates de látex, revestimentos aquosos e pinturas tendo estabilidade de congelamento-degelo e métodos para usar os mesmos | |
| HUE066960T2 (hu) | Tasakos típusú másodlagos akkumulátor, és tasak másodlagos akkumulátorhoz | |
| BR112017004141A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| AR061348A1 (es) | Preparados estables de laquinimod | |
| FR2914009B1 (fr) | Joints retractables actifs pour turbomachines | |
| NO20076596L (no) | Fremgangsmate for dynamisk oppdatering av en indeks og en sokemotor som implementerer samme | |
| DK2545047T3 (da) | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) | |
| WO2011101751A3 (en) | Contextual correlation engine | |
| WO2013076507A3 (en) | Platelet lysate gel | |
| EA201000258A1 (ru) | Новые гербициды | |
| EP2584410A4 (en) | CARRIER CORE FOR AN ELECTRONOGRAPH DEVELOPER, CARRIER FOR AN ELECTRONOGRAPHIC DEVELOPER AND ELECTRONOGRAPHIC DEVELOPER | |
| EA201370149A1 (ru) | Антагонисты рецептора | |
| EP4018690A4 (en) | PROVISION OF LOCATION INFORMATION | |
| BR112017004134A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| EP2728810A4 (en) | INFORMATION TRANSMISSION METHOD, PACKET DATA GATEWAY, AND FUNCTION OF POLICY AND INVOICING RULES | |
| WO2013156546A3 (en) | Endoprosthesis leakage analysis | |
| EA201000069A1 (ru) | Новые гербициды |